Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Eli Lilly entered June 2026 with something most pharmaceutical companies spend years chasing: clinical data so compelling that competitors can barely keep pace. At the American Diabetes Association’s annual Scientific Sessions, the company unveiled extended trial results for retatrutide. Clinicians, analysts, and investors all took notice.
The drug works differently from anything currently approved. While existing injectables like Zepbound and Wegovy target one or two gut hormones, retatrutide activates three receptor pathways at once: GIP, GLP-1, and glucagon. That triple-hormone approach appears to drive substantially greater weight loss than today’s approved options.
The TRIUMPH-1 Phase 3 trial ran for 104 weeks. Patients with class 2 obesity lost an average of 30.3% of their body weight. At 80 weeks, those on the highest dose lost roughly 70 pounds, a 28.3% reduction. Nearly half of the participants on that dose achieved 30% or greater weight loss. Researchers caution against direct comparisons to bariatric surgery, but the figures are generating serious discussion in obesity medicine.
Retatrutide also delivered strong results in type 2 diabetes patients. In the TRANSCEND-T2D-1 trial, HbA1c levels dropped by nearly two percentage points on the 12 mg dose. The placebo group saw less than a one-point drop. Patients also reported meaningful improvements in knee osteoarthritis pain and obstructive sleep apnea. Both conditions frequently develop alongside obesity, and few single medications address them together.
Lilly also shared early data on eloralintide, an experimental agent that targets the amylin pathway. It showed better tolerability than current GLP-1 therapies. For patients who struggle with persistent nausea or gastrointestinal side effects, that distinction could matter considerably.
The ADA conference was not a Lilly showcase alone. Roche, AstraZeneca, Pfizer, and several smaller companies all presented obesity data. That activity effectively transformed what was once a diabetes-focused meeting into a weight management forum. The shift reflects just how large the clinical and commercial opportunity has become.
Roche reported 22.7% body weight loss in a mid-stage trial of enicepatide, its experimental dual-acting injectable. Gastrointestinal side effects remained comparable to approved GLP-1 receptor agonist therapies. Roche also highlighted petrelintide, a weekly amylin-based injection it develops with Zealand Pharma. The company describes its tolerability profile as nearly placebo-level, which could help patients stay on treatment longer.
AstraZeneca presented data on elecoglipron, an oral GLP-1 agent. The company plans to use it as the foundation of a broader metabolic strategy. Future combinations with its existing kidney, heart, and diabetes medicines remain part of that longer-term plan.
Despite the competitive activity, analysts offered a measured verdict. RBC Capital Markets described the data from Novo Nordisk, Roche, and others as broadly on par with existing approved drugs. None, however, could match what Lilly’s pipeline now offers. UBS analysts wrote that retatrutide gives Lilly’s obesity franchise durability extending well into the next decade, even as pricing pressure builds and generic competition for earlier therapies approaches.
Markets reacted quickly after the conference. Lilly’s shares closed 1.6% higher on the first trading day. Novo Nordisk fell 4.2%. Roche, Pfizer, and Zealand Pharma all lost ground. Over the prior 12 months, Lilly gained roughly 42% while Novo dropped approximately 47%.
Roche’s head of cardiovascular and metabolic product development noted that obesity is complex and heterogeneous. No single drug will serve every patient. Different patients will weigh efficacy, tolerability, route of administration, and cost differently. That reality may eventually support a broader market with multiple agents serving distinct patient segments. For now, the data put Lilly in a category of its own.
